Open AccessDecarboxylated osteocalcin, a possible drug for type 2 diabetes, triggers glucose uptake in MG63 cells
Author(s) -
Shi Jin,
Xiaoai Chang,
Jing Wen,
Jing Yang,
Na Ao,
Keying Zhang,
Linna Suo,
Junying Du
Publication year - 2021
Publication title -
world journal of diabetes
Language(s) - English
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v12.i7.1102
Subject(s) - medicine , diabetes mellitus , type 2 diabetes , drug , osteocalcin , pharmacology , endocrinology , biochemistry , biology , alkaline phosphatase , enzyme
Uncarboxylated osteocalcin (GluOC) has been reported to improve glucose metabolism, prevent type 2 diabetes, and decrease the severity of obesity in mice with type 2 diabetes. GluOC can increase glucose uptake in a variety of cells. Glucose metabolism is the main source of energy for osteoblast proliferation and differentiation. We hypothesized that decarboxylated osteocalcin (dcOC), a kind of GluOC, can increase glucose uptake in MG63 cells (osteoblast-like osteosarcoma cells) and influence their proliferation and differentiation.